BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...that included crossover investors RA Capital and BVF Partners.In...
...helicase Danielle Golovin BMS-986165 Nimbus Therapeutics LLC Gilead Sciences Inc. RA Capital Management BVF Partners Atlas...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...and Mission BioCapital and new investors including BVF Partners...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...backers, joined all of Olema’s existing institutional investors in the round. Its existing investors include BVF Partners...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...and principal financial officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), and chief strategy officer of Sanofi S.A. BVF Partners...
BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

...Logos Capital. Also investing were existing backers BVF Partners...
...Inc. Boxer Capital Cormorant Asset Management Samsara BioCapital Janus Henderson Investors Logos Capital BVF Partners Perceptive...
BioCentury | Aug 28, 2020
Deals

Principia shareholder still wants ‘more favorable outcome’ as filing reveals escalating Sanofi bids ahead of deal

...offering roughly a third more cash, according to a letter filed with regulators this week.Although BVF Partners...
BioCentury | Jul 24, 2020
Finance

Olema aims to deploy $54M round to carve its niche in breast cancer

...therapy, which is administered daily, into a Phase I/II trial this year for breast cancer. BVF Partners...
...understanding.” Olema Oncology had raised $6.1 million in a 2018 series A round led by BVF Partners...
...growth factor receptor 2 PI3Kα - Phosphoinositide 3-kinase α Danielle Golovin, Staff Writer Faslodex, fulvestrant (ICI 182,780) Olema Pharmaceuticals BVF Partners Logos...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...round led by Aisling. Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management and BVF Partners...
...million Investors: Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management and BVF Partners...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Investments and QUAD Investment Management. Existing investors joining them were Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Lenden is president, COO and co-founder of Autobahn Therapeutics. Also participating in the round are BVF Partners...
...Number of employees: 12 Funds raised: $94 million Investors: Arch Venture Partners, Cowen Healthcare Investments, BVF Partners...
Items per page:
1 - 10 of 70
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...that included crossover investors RA Capital and BVF Partners.In...
...helicase Danielle Golovin BMS-986165 Nimbus Therapeutics LLC Gilead Sciences Inc. RA Capital Management BVF Partners Atlas...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...and Mission BioCapital and new investors including BVF Partners...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...backers, joined all of Olema’s existing institutional investors in the round. Its existing investors include BVF Partners...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...and principal financial officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), and chief strategy officer of Sanofi S.A. BVF Partners...
BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

...Logos Capital. Also investing were existing backers BVF Partners...
...Inc. Boxer Capital Cormorant Asset Management Samsara BioCapital Janus Henderson Investors Logos Capital BVF Partners Perceptive...
BioCentury | Aug 28, 2020
Deals

Principia shareholder still wants ‘more favorable outcome’ as filing reveals escalating Sanofi bids ahead of deal

...offering roughly a third more cash, according to a letter filed with regulators this week.Although BVF Partners...
BioCentury | Jul 24, 2020
Finance

Olema aims to deploy $54M round to carve its niche in breast cancer

...therapy, which is administered daily, into a Phase I/II trial this year for breast cancer. BVF Partners...
...understanding.” Olema Oncology had raised $6.1 million in a 2018 series A round led by BVF Partners...
...growth factor receptor 2 PI3Kα - Phosphoinositide 3-kinase α Danielle Golovin, Staff Writer Faslodex, fulvestrant (ICI 182,780) Olema Pharmaceuticals BVF Partners Logos...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...round led by Aisling. Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management and BVF Partners...
...million Investors: Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management and BVF Partners...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Investments and QUAD Investment Management. Existing investors joining them were Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...Lenden is president, COO and co-founder of Autobahn Therapeutics. Also participating in the round are BVF Partners...
...Number of employees: 12 Funds raised: $94 million Investors: Arch Venture Partners, Cowen Healthcare Investments, BVF Partners...
Items per page:
1 - 10 of 70